Recent Publications:

  1. Paul, P., Choong, C., Heinemann, J., Al-Hallaf, R., Agha, Z., Ganatra, S., Abdulrahman, L., Sinha, A., Kumar H., Nourbakhsh. B., Hamad, A. R. A. (2025). The Lasting Impact of IL-2: Approaching 50 Years of Advancing Immune Tolerance, Cancer Immunotherapies, and Autoimmune Diseases. Immunological Investigations, 1–15. https://doi.org/10.1080/08820139.2025.2479609
  2. Sadasivam M, Noel S, Lee K, Gharaie S, Rabb H, Hamad ARA. Renal Tubular Epithelial Cell-Derived IL-7 Drives Expansion and Protective Effects of Double-Negative T Cells in Acute Kidney Injury. Immunol Invest. 2025 Feb 6;:1-14. doi: 10.1080/08820139.2025.2462537. [Epub ahead of print] PubMed PMID: 39912351; NIHMSID:NIHMS2054299.
  3. Majety N, Ahmed R, Al-Hallaf R, Paul P, Giwa A, Heinemann J, Agha Z, Choong C, Donner T, Jie C, Hamad ARA. Invariant VD and DJ Motifs Define a Novel Class of Human Antibodies and TCRs Prototyped by antigen receptors of Dual-Expresser Lymphocytes. Immunol Invest. 2024 Oct;53(7):1125-1140. doi: 10.1080/08820139.2024.2383736. Epub 2024 Sep 13. PubMed PMID: 39268869.
  4. Sadasivam M, Jie C, Hamad ARA. Renal tubular epithelial cells are constitutive non-cognate stimulators of resident T cells. Cell Rep. 2023 Oct 31;42(10):113210. doi: 10.1016/j.celrep.2023.113210. Epub 2023 Oct 4. PubMed PMID: 37796661; PubMed Central PMCID: PMC11259314.
  5. Song Y, Bell DR, Ahmed R, Chan KC, Lee S, Hamad ARA, Zhou R. A mutagenesis study of autoantigen optimization for potential T1D vaccine design. Proc Natl Acad Sci U S A. 2023 Apr 18;120(16):e2214430120. doi: 10.1073/pnas.2214430120. Epub 2023 Apr 11. PubMed PMID: 37040399; PubMed Central PMCID: PMC10120010.
  6. Ahmed R, Ananth K, Omidian Z, Majety N, Zhang H, Hamad ARA. Detection, sorting, and immortalization of dual expresser lymphocytes from human peripheral blood samples. STAR Protoc. 2021 Dec 17;2(4):100925. doi: 10.1016/j.xpro.2021.100925. eCollection 2021 Dec 17. PubMed PMID: 34755121; PubMed Central PMCID: PMC8564191.
  7. Ahmed R, Omidian Z, Giwa A, Donner T, Jie C, Hamad ARA. A reply to “TCR+/BCR+ dual-expressing cells and their associated public BCR clonotype are not enriched in type 1 diabetes”. Cell. 2021 Feb 4;184(3):840-843. doi: 10.1016/j.cell.2020.11.036. PubMed PMID: 33545037; PubMed Central PMCID: PMC7935028.
  8. Ahmed R, Omidian Z, Giwa A, Cornwell B, Majety N, Bell DR, Lee S, Zhang H, Michels A, Desiderio S, Sadegh-Nasseri S, Rabb H, Gritsch S, Suva ML, Cahan P, Zhou R, Jie C, Donner T, Hamad ARA. A Public BCR Present in a Unique Dual-Receptor-Expressing Lymphocyte from Type 1 Diabetes Patients Encodes a Potent T Cell Autoantigen. 2019 May 30;177(6):1583-1599.e16. doi: 10.1016/j.cell.2019.05.007.

For Other Published Work See Here:

https://www.ncbi.nlm.nih.gov/myncbi/abdel.hamad.1/bibliography/public/

Key Publications That Led to Discovery of DEs

  1. Xiao, X., Mohamood, A.S., Uddin, S., Gutfreund, R., Nakata, S., Marshall, A., Kimura, H., Caturegli, P., Womer, K.L., Huang, Y., J. Schneck, Hideo Yagita and Abdel Rahim Hamad. Inhibition of Fas ligand in NOD mice unmasks a protective role for IL-10 against insulitis development. Am J Pathol. 2011;179:752-32. PMID 21718680
  2. Immunotherapy for Type 1 Diabetes: Necessity, Challenges and Unconventional Opportunities. Type 1 Diabetes / Book 1″, ISBN 978-953-307. 2011.
  3. Mohamood AS, Trujillo CJ, Zheng D, Jie C, Murillo FM, Schneck JP and A. R. Hamad. Gld mutation of Fas ligand increases the frequency and upregulates cell survival genes in CD25+CD4+ Treg Cells. Int Immunol. 2006; 18:1265. PMID 16769751
  4. Mohamood A., M Guler, X. Zuoxiang, D. Zheng, Y. Wang, H. Yagita, J Schneck and A. R. Hamad. 2007. Protection from autoimmune diabetes and T cell lymphoproliferation-induced by FasL mutation are differentially regulated and can be uncoupled pharmacologically. Am J Pathol 171:97. PMID 17591957